Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Béthune MP, De Smedt G, Woodfall B, Picchio G.

AIDS. 2010 Feb 20;24(4):503-14. doi: 10.1097/QAD.0b013e32833677ac.

PMID:
20051805
[PubMed - indexed for MEDLINE]
2.

Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.

Vingerhoets J, Nijs S, Tambuyzer L, Hoogstoel A, Anderson D, Picchio G.

Antivir Ther. 2012;17(8):1571-9. doi: 10.3851/IMP2275. Epub 2012 Aug 7.

PMID:
22869341
[PubMed - indexed for MEDLINE]
3.

Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Béthune MP, Picchio G.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1197-205. doi: 10.1089/aid.2009.0302. Epub 2010 Sep 20.

PMID:
20854144
[PubMed - indexed for MEDLINE]
4.

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

Schiller DS, Youssef-Bessler M.

Clin Ther. 2009 Apr;31(4):692-704. doi: 10.1016/j.clinthera.2009.04.020. Review.

PMID:
19446143
[PubMed - indexed for MEDLINE]
5.

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):18-22. doi: 10.1097/QAI.0b013e3182237f74.

PMID:
21637112
[PubMed - indexed for MEDLINE]
6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
7.

Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

Trottier B, Di Perri G, Madruga JV, Peeters M, Vingerhoets J, Picchio G, Woodfall BJ.

HIV Clin Trials. 2010 Jul-Aug;11(4):175-85. doi: 10.1310/hct1104-175.

PMID:
20974573
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.

AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.

PMID:
19710593
[PubMed - indexed for MEDLINE]
9.

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.

Poveda E, de Mendoza C, Pattery T, González Mdel M, Villacian J, Soriano V.

AIDS. 2008 Nov 12;22(17):2395-8. doi: 10.1097/QAD.0b013e32831692fb.

PMID:
18981781
[PubMed - indexed for MEDLINE]
10.

Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).

Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M; Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group.

HIV Med. 2010 Sep;11(8):530-4. doi: 10.1111/j.1468-1293.2009.00819.x. Epub 2010 Mar 8.

PMID:
20236364
[PubMed - indexed for MEDLINE]
11.

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2010 Feb;54(2):728-33. doi: 10.1128/AAC.01335-09. Epub 2009 Dec 14.

PMID:
20008779
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.

Clumeck N, Cahn P, Molina JM, Mills A, Nijs S, Vingerhoets J, Witek J.

Int J STD AIDS. 2010 Nov;21(11):738-40. doi: 10.1258/ijsa.2010.010139.

PMID:
21187353
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, Towner W, Haubrich R, Nijs S, Vingerhoets J, Woodfall B, Witek J.

Antivir Ther. 2010;15(7):1045-52. doi: 10.3851/IMP1662.

PMID:
21041921
[PubMed - indexed for MEDLINE]
14.

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.

Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J.

AIDS Res Hum Retroviruses. 2011 Dec;27(12):1271-5. doi: 10.1089/aid.2011.0049. Epub 2011 Jun 11.

PMID:
21557669
[PubMed - indexed for MEDLINE]
15.

Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.

Croxtall JD.

Drugs. 2012 Apr 16;72(6):847-69. doi: 10.2165/11209110-000000000-00000. Review.

PMID:
22512366
[PubMed - indexed for MEDLINE]
16.

Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.

Yeni P, Mills A, Peeters M, Vingerhoets J, Kakuda TN, De Smedt G, Woodfall B.

Curr HIV Res. 2010 Oct;8(7):564-76. Review.

PMID:
20946097
[PubMed - indexed for MEDLINE]
17.

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM; AIDS Clinical Trials Group Study 359 Protocol Team.

AIDS Res Hum Retroviruses. 2008 May;24(5):685-94. doi: 10.1089/aid.2007.0127.

PMID:
18462083
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

TMC125-C223 Writing Group, Nadler JP, Berger DS, Blick G, Cimoch PJ, Cohen CJ, Greenberg RN, Hicks CB, Hoetelmans RM, Iveson KJ, Jayaweera DS, Mills AM, Peeters MP, Ruane PJ, Shalit P, Schrader SR, Smith SM, Steinhart CR, Thompson M, Vingerhoets JH, Voorspoels E, Ward D, Woodfall B.

AIDS. 2007 Mar 30;21(6):F1-10.

PMID:
17413684
[PubMed - indexed for MEDLINE]
19.

Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W.

Curr HIV Res. 2008 Sep;6(5):474-6.

PMID:
18855659
[PubMed - indexed for MEDLINE]
20.

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.

Cotte L, Trabaud MA, Tardy JC, Brochier C, Gilibert RP, Miailhes P, Trépo C, André P.

J Med Virol. 2009 Apr;81(4):672-7. doi: 10.1002/jmv.21461.

PMID:
19235860
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk